ASND | Ascendis Pharma A/S | [NASD]
Index- P/E- EPS (ttm)-10.90 Insider Own0.07% Shs Outstand57.33M Perf Week-4.85%
Market Cap4.85B Forward P/E- EPS next Y-0.01 Insider Trans0.00% Shs Float57.29M Perf Month22.61%
Income-609.50M PEG- EPS next Q- Inst Own123.56% Short Float / Ratio7.74% / 5.37 Perf Quarter-22.78%
Sales83.50M P/S58.04 EPS this Y-48.50% Inst Trans3.26% Short Interest4.43M Perf Half Y-26.01%
Book/sh3.20 P/B26.81 EPS next Y50.00% ROA-48.80% Target Price138.57 Perf Year-3.31%
Cash/sh11.11 P/C7.72 EPS next 5Y- ROE-152.70% 52W Range64.33 - 134.52 Perf YTD-29.76%
Dividend- P/FCF- EPS past 5Y-23.10% ROI-73.50% 52W High-36.23% Beta0.51
Dividend %- Quick Ratio3.30 Sales past 5Y101.80% Gross Margin83.90% 52W Low33.34% ATR3.80
Employees797 Current Ratio4.10 Sales Q/Q394.10% Oper. Margin- RSI (14)41.90 Volatility3.16% 4.31%
OptionableYes Debt/Eq3.02 EPS Q/Q10.60% Profit Margin- Rel Volume0.47 Prev Close89.75
ShortableYes LT Debt/Eq2.87 EarningsApr 27 AMC Payout- Avg Volume825.85K Price85.78
Recom2.00 SMA20-6.86% SMA50-4.90% SMA200-19.38% Volume379,250 Change-4.42%
Date Action Analyst Rating Change Price Target Change
Apr-05-23Downgrade Oppenheimer Outperform → Perform
Apr-04-23Downgrade Morgan Stanley Overweight → Equal-Weight $151 → $108
Apr-03-23Downgrade Credit Suisse Outperform → Neutral
Oct-20-22Initiated Goldman Buy $174
Aug-30-22Resumed Berenberg Buy $166
Mar-28-22Resumed Wedbush Outperform $163
Mar-15-22Upgrade BofA Securities Neutral → Buy $148 → $161
Mar-01-22Initiated Citigroup Buy $187
Feb-14-22Upgrade Oppenheimer Perform → Outperform $170
Jan-06-22Initiated Cowen Market Perform $136
May-25-23 08:30AM
May-13-23 07:00PM
May-03-23 04:15PM
May-01-23 11:45AM
07:00AM Loading…
Apr-27-23 04:01PM
Apr-22-23 08:11AM
Apr-13-23 08:30AM
Apr-12-23 09:18AM
Apr-06-23 04:22PM
Apr-04-23 12:43PM
Apr-03-23 04:07PM
07:05AM Loading…
Mar-17-23 03:35AM
Mar-10-23 08:00AM
Feb-20-23 08:08AM
Feb-18-23 07:23AM
Feb-16-23 04:01PM
Feb-07-23 08:00AM
Jan-30-23 11:46PM
Jan-08-23 05:00PM
Jan-04-23 08:00AM
Jan-03-23 08:00AM
Dec-26-22 08:38PM
Dec-05-22 08:00AM
08:30AM Loading…
Nov-22-22 08:30AM
Nov-14-22 07:00AM
Nov-13-22 06:15PM
Nov-11-22 12:10PM
Nov-02-22 04:01PM
Oct-31-22 08:00AM
Oct-26-22 08:00AM
Oct-12-22 09:55AM
Oct-11-22 11:38PM
Oct-03-22 08:00AM
Sep-12-22 08:00AM
Sep-01-22 08:00AM
Aug-31-22 11:12AM
Aug-10-22 04:01PM
Aug-09-22 08:06AM
Aug-04-22 08:00AM
Aug-01-22 07:00AM
Jun-16-22 11:42AM
Jun-07-22 08:00AM
May-23-22 08:00AM
May-12-22 04:09PM
May-11-22 04:01PM
May-10-22 11:13AM
May-09-22 08:00AM
May-04-22 04:05PM
May-02-22 11:08AM
May-01-22 07:00AM
Apr-04-22 06:00AM
Mar-24-22 10:41PM
Mar-23-22 04:01PM
Mar-14-22 07:57AM
Mar-13-22 05:53PM
Mar-03-22 09:30AM
Mar-02-22 04:01PM
Feb-25-22 08:00AM
Feb-10-22 04:05PM
Feb-08-22 01:38PM
Feb-04-22 05:38PM
Feb-02-22 01:38PM
Jan-25-22 07:09AM
Jan-24-22 12:48PM
Jan-14-22 11:34AM
Jan-13-22 11:44AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-24-21 12:38AM
Dec-18-21 12:38AM
Dec-17-21 11:38PM
Dec-14-21 08:00AM
Dec-13-21 04:38PM
Dec-11-21 06:25PM
Dec-09-21 08:38PM
Dec-08-21 07:38PM
Dec-07-21 05:41PM
Nov-25-21 07:35AM
Nov-23-21 11:07AM
Nov-19-21 07:40AM
Nov-18-21 04:42PM
Nov-17-21 04:05PM
Nov-15-21 11:00AM
Nov-12-21 07:22AM
Nov-10-21 10:00PM
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.